Alissa Hsu Lynch
About Alissa Hsu Lynch
Alissa Hsu Lynch (age 56) has served as an independent director of The Honest Company since December 2023. She previously led MedTech Strategy and Solutions for Google Cloud (2020–2023) and spent 20 years at Johnson & Johnson, including Vice President, Medical Devices (2016–2020). Lynch holds an MBA from Columbia Business School, an AB from Princeton University, and an NACD CERT Certificate in Cyber-Risk Oversight. External engagements include Trustee of American Ballet Theatre, Executive in Residence at Columbia Business School, and Henry Crown Fellow of The Aspen Institute .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Google Cloud (Google LLC) | Global Lead, MedTech Strategy & Solutions | 2020–2023 | Led healthcare transformation initiatives with Fortune 500 customers |
| Johnson & Johnson | Consumer marketing, strategy, and GM roles; VP, Medical Devices | ~2000–2020; VP 2016–2020 | Senior leadership in medical devices and consumer marketing |
| Professional modern dancer | Performer | ~6 years (pre-J&J) | Not applicable |
External Roles
| Organization | Role | Tenure/Status |
|---|---|---|
| American Ballet Theatre | Board of Trustees | Current |
| Columbia Business School | Executive in Residence | Current |
| The Aspen Institute | Henry Crown Fellow | Current |
| Pulmonx Corporation | Director | July 2021–May 2024 (former) |
Board Governance
| Item | Details |
|---|---|
| Independence | Board determined Lynch is independent under Nasdaq listing standards; only the CEO and former Chief Creative Officer are non-independent . |
| Committees (2024) | Audit Committee (member), Nominating & Corporate Governance Committee (member). Not a chair . |
| Committee independence | All Audit and Nominating Committee members met Nasdaq independence requirements . |
| Committee duties (relevant to Lynch’s roles) | Audit: financial reporting, internal controls, related-party transaction approval, cybersecurity/IT risks oversight . Nominating: board composition, governance guidelines, ESG oversight, succession planning, board/committee evaluations . |
| Meetings | Board met 4x in FY2024; Audit 4x; Nominating 4x . |
| Attendance | Each director attended ≥75% of board and applicable committee meetings in FY2024 . |
| Board leadership | Independent Chair (James D. White); executive sessions at each regularly scheduled board and committee meeting . |
Fixed Compensation
| Component (Policy) | Amount ($) | Notes |
|---|---|---|
| Board annual cash retainer | 50,000 | Non-employee directors |
| Audit Committee member | 15,000 | Chair: 20,000 |
| Compensation Committee member | 7,500 | Chair: 15,000 |
| Nominating & Corporate Governance Committee member | 5,000 | Chair: 10,000 |
| Chair of the Board | 125,000 | Non-executive chair |
| Lead Independent Director | 70,000 | If applicable |
Director Compensation (FY2024)
| Name | Cash Fees ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| Alissa Hsu Lynch | 57,065 | 166,565 | 223,630 |
Notes:
- Policy allows directors to elect to receive cash retainers in RSUs (“Retainer Grant”); Bayne and Hartung elected this in 2024, Lynch did not .
Performance Compensation
Policy structure and vesting
- Initial Grant: RSUs valued at $185,000, vesting in three equal annual installments on the 1-, 2-, and 3-year anniversaries .
- Annual Grant: RSUs valued at $185,000, vest fully by the earlier of 1-year from grant or immediately prior to next annual meeting, subject to service .
- Retainer Grant option: Directors may elect to receive all cash retainers as RSUs that vest in equal quarterly installments over the fiscal year; settlement deferral elections permitted .
- Accelerated vesting: RSUs fully vest upon death, disability, or immediately prior to a change in control .
RSU Grants (FY2024)
| Director | RSUs Granted (shares) | Grant Date Fair Value ($) |
|---|---|---|
| Alissa Hsu Lynch | 60,569 | 166,565 |
Outstanding Equity Awards (12/31/2024)
| Director | Options Outstanding | Stock Awards Outstanding (Unvested RSUs) |
|---|---|---|
| Alissa Hsu Lynch | — | 135,841 |
Performance metrics tied to director compensation
| Metric Category | Application to Lynch |
|---|---|
| TSR, revenue/EBITDA, ESG goals | Not applicable; non-employee director pay uses time-based RSUs and cash retainers (no performance-conditioned PSUs disclosed) . |
Other Directorships & Interlocks
| Company | Sector | Role | Interlocks/Conflicts |
|---|---|---|---|
| Pulmonx Corporation | Medical devices | Director (Jul 2021–May 2024) | No HNST-related interlocks disclosed; Audit Committee oversees related-party transactions . |
Expertise & Qualifications
- Technology and healthcare data strategy (Google Cloud MedTech) .
- Consumer and medical devices leadership (Johnson & Johnson; VP Medical Devices) .
- Governance and cyber oversight credential (NACD CERT Certificate in Cyber-Risk Oversight) .
- Arts governance and academic engagement (ABT Trustee; Columbia EIR; Aspen Henry Crown Fellow) .
Equity Ownership
Security Ownership (as of 3/31/2025; 110,229,634 shares outstanding)
| Holder | Beneficial Shares | % of Outstanding |
|---|---|---|
| Alissa Hsu Lynch | 152,201 | <1% (“*” per proxy) |
Breakdown (footnote detail)
| Category | Shares |
|---|---|
| Common shares held | 91,632 |
| RSUs vesting within 60 days | 60,569 |
| Unvested RSUs beyond 60 days (derived) | 75,272 (135,841 total unvested RSUs at 12/31/2024 minus 60,569 near-vesting) |
Insider Trades (Form 4)
| Filing Date | Transaction Date | Type | Shares | Price ($) | Post-Transaction Ownership | SEC Link |
|---|---|---|---|---|---|---|
| 2025-05-30 | 2025-05-28 | A – Award | 38,252 | 0.00 | 272,736 | |
| 2025-01-03 | 2025-01-01 | A – Award | 9,348 | 7.49 | 234,484 | |
| 2024-05-23 | 2024-05-22 | A – Award | 60,569 | 0.00 | 225,136 |
Governance Assessment
-
Independence and committee placement: Lynch is independent and sits on Audit and Nominating, both central to financial integrity, conflict oversight, ESG, and succession planning—aligns with her cyber and tech credentials .
-
Attendance and engagement: Board and committees met 4x each; all directors, including Lynch, met the ≥75% attendance threshold—adequate engagement for a relatively new director .
-
Alignment via equity: Lynch received the standard annual RSU grant and holds a meaningful number of unvested RSUs; policy permits converting cash retainers to RSUs and deferrals, supporting ownership alignment though Lynch did not elect fee-to-RSU in 2024 .
-
Oversight of conflicts: Audit Committee explicitly approves related-party transactions; no Lynch-specific related-party transactions disclosed; Jessica Alba’s Name and Likeness Agreement terminated April 2024, reducing historical related-party exposure at the company level .
-
Risk indicators and red flags:
- Single-trigger accelerated vesting of director RSUs upon change in control (vests immediately prior) could be viewed as investor-unfriendly versus double-trigger designs—monitor equity grant practices over time .
- Section 16(a) compliance: company indicates full compliance (no delinquent filings)—positive governance signal .
- No pledging or hedging disclosures specific to Lynch found; board maintains Insider Trading and Hedging Policy sections, but details are not provided in the cited text .
-
Compensation structure: Director pay targets peer-group median and uses an independent consultant (Semler Brossy), with clear role-based cash retainers and standardized RSU grants—transparent and consistent with best practices .
-
Overall view: Lynch’s background in tech/cyber and medtech strengthens Audit and ESG/succession oversight; attendance and independence are satisfactory; no personal conflicts identified; monitor potential optics of single-trigger RSU vesting on change in control and continued equity accumulation for alignment .